Laura A Petrillo1, Areej El-Jawahri2, Emily R Gallagher2, Vicki A Jackson3, Jennifer S Temel2, Joseph A Greer4. 1. Division of Palliative Care and Geriatrics, Massachusetts General Hospital (L.A.P., V.A.J.), Boston, Massachusetts, USA. Electronic address: lpetrillo2@mgh.harvard.edu. 2. Division of Hematology and Oncology, Massachusetts General Hospital (A.E.-J., E.R.G., J.S.T.), Boston, Massachusetts, USA. 3. Division of Palliative Care and Geriatrics, Massachusetts General Hospital (L.A.P., V.A.J.), Boston, Massachusetts, USA. 4. Department of Psychiatry, Massachusetts General Hospital (J.A.G.), Boston, Massachusetts, USA.
Abstract
CONTEXT: Targeted therapy has revolutionized lung cancer treatment and markedly increased survival, though data are lacking on patient-reported and end-of-life (EOL) outcomes among patients receiving targeted therapy. OBJECTIVES: This study aimed to compare quality of life (QOL), symptoms, prognostic communication, and EOL care between patients receiving targeted therapy and patients with lung cancer without targetable mutations. METHODS: In this secondary analysis of a randomized trial of early palliative care in advanced lung cancer (n=154), we compared change in QOL and symptoms (per the Functional Assessment of Cancer Treatment [FACT]-Lung scale) over 24 weeks among patients with lung cancer receiving targeted therapy versus those without targetable mutations using linear mixed effects models, adjusted for receipt of palliative care, age and gender. We also compared prognostic communication and decedents' EOL health care utilization using logistic regression, adjusted for palliative care. RESULTS: Compared to individuals without targetable mutations, patients receiving targeted therapy (n=35) reported greater improvements in QOL (FACT-General B=0.46; 95% CI=0.19, 0.73) and symptoms (FACT-Lung Cancer Subscale B=0.12; 95% CI=0.03, 0.20) over time, independent of palliative care. Patients receiving targeted therapy were also more likely to report they rarely discussed prognosis with their clinicians (OR=2.59, 95% CI=1.01, 6.63) and were more likely to receive cancer-directed therapy in their last 14 days of life (OR=14.98, 95% CI=4.08, 54.96). CONCLUSIONS: Relative to patients without targetable mutations, patients with lung cancer who receive targeted therapy experience improved QOL and symptoms, are less likely to discuss prognosis early in their illness course, and more likely to continue treatment until death and die in the hospital.
CONTEXT: Targeted therapy has revolutionized lung cancer treatment and markedly increased survival, though data are lacking on patient-reported and end-of-life (EOL) outcomes among patients receiving targeted therapy. OBJECTIVES: This study aimed to compare quality of life (QOL), symptoms, prognostic communication, and EOL care between patients receiving targeted therapy and patients with lung cancer without targetable mutations. METHODS: In this secondary analysis of a randomized trial of early palliative care in advanced lung cancer (n=154), we compared change in QOL and symptoms (per the Functional Assessment of Cancer Treatment [FACT]-Lung scale) over 24 weeks among patients with lung cancer receiving targeted therapy versus those without targetable mutations using linear mixed effects models, adjusted for receipt of palliative care, age and gender. We also compared prognostic communication and decedents' EOL health care utilization using logistic regression, adjusted for palliative care. RESULTS: Compared to individuals without targetable mutations, patients receiving targeted therapy (n=35) reported greater improvements in QOL (FACT-General B=0.46; 95% CI=0.19, 0.73) and symptoms (FACT-Lung Cancer Subscale B=0.12; 95% CI=0.03, 0.20) over time, independent of palliative care. Patients receiving targeted therapy were also more likely to report they rarely discussed prognosis with their clinicians (OR=2.59, 95% CI=1.01, 6.63) and were more likely to receive cancer-directed therapy in their last 14 days of life (OR=14.98, 95% CI=4.08, 54.96). CONCLUSIONS: Relative to patients without targetable mutations, patients with lung cancer who receive targeted therapy experience improved QOL and symptoms, are less likely to discuss prognosis early in their illness course, and more likely to continue treatment until death and die in the hospital.
Authors: Nasser Hanna; David Johnson; Sarah Temin; Sherman Baker; Julie Brahmer; Peter M Ellis; Giuseppe Giaccone; Paul J Hesketh; Ishmael Jaiyesimi; Natasha B Leighl; Gregory J Riely; Joan H Schiller; Bryan J Schneider; Thomas J Smith; Joan Tashbar; William A Biermann; Gregory Masters Journal: J Clin Oncol Date: 2017-08-14 Impact factor: 44.544
Authors: Jennifer S Temel; Joseph A Greer; Sonal Admane; Emily R Gallagher; Vicki A Jackson; Thomas J Lynch; Inga T Lennes; Connie M Dahlin; William F Pirl Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: Holly G Prigerson; Yuhua Bao; Manish A Shah; M Elizabeth Paulk; Thomas W LeBlanc; Bryan J Schneider; Melissa M Garrido; M Carrington Reid; David A Berlin; Kerin B Adelson; Alfred I Neugut; Paul K Maciejewski Journal: JAMA Oncol Date: 2015-09 Impact factor: 31.777
Authors: G Chen; J Feng; C Zhou; Y-L Wu; X-Q Liu; C Wang; S Zhang; J Wang; S Zhou; S Ren; S Lu; L Zhang; C-P Hu; C Hu; Y Luo; L Chen; M Ye; J Huang; X Zhi; Y Zhang; Q Xiu; J Ma; L Zhang; C You Journal: Ann Oncol Date: 2013-03-01 Impact factor: 32.976
Authors: Jessica R Bauman; Zofia Piotrowska; Alona Muzikansky; Emily Gallagher; Emily Scribner; Brandon Temel; Lecia V Sequist; Rebecca S Heist; Jennifer S Temel Journal: J Palliat Med Date: 2016-09-14 Impact factor: 2.947
Authors: Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245
Authors: C von Plessen; B Bergman; O Andresen; R M Bremnes; S Sundstrom; M Gilleryd; R Stephens; J Vilsvik; U Aasebo; S Sorenson Journal: Br J Cancer Date: 2006-10-03 Impact factor: 7.640
Authors: Yvonne Nartey; Laila J Tata; Aamir Khakwani; Vanessa Beattie; Paul Beckett; Richard B Hubbard; Iain Stewart Journal: Support Care Cancer Date: 2022-02-01 Impact factor: 3.359